Cargando…

Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort

BACKGROUND: Visual outcome is one of the main issues in the treatment of optic pathway glioma in childhood. Although the prognostic factors of low vision have been discussed extensively, no reliable indicators for visual loss exist. Therefore, we aimed to define initial and evolving factors associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakotonjanahary, Josué, Gravier, Nicolas, Lambron, Julien, De Carli, Emilie, Toulgoat, Frédérique, Delion, Matthieu, Pellier, Isabelle, Rialland, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407847/
https://www.ncbi.nlm.nih.gov/pubmed/30849081
http://dx.doi.org/10.1371/journal.pone.0212107
_version_ 1783401648182263808
author Rakotonjanahary, Josué
Gravier, Nicolas
Lambron, Julien
De Carli, Emilie
Toulgoat, Frédérique
Delion, Matthieu
Pellier, Isabelle
Rialland, Xavier
author_facet Rakotonjanahary, Josué
Gravier, Nicolas
Lambron, Julien
De Carli, Emilie
Toulgoat, Frédérique
Delion, Matthieu
Pellier, Isabelle
Rialland, Xavier
author_sort Rakotonjanahary, Josué
collection PubMed
description BACKGROUND: Visual outcome is one of the main issues in the treatment of optic pathway glioma in childhood. Although the prognostic factors of low vision have been discussed extensively, no reliable indicators for visual loss exist. Therefore, we aimed to define initial and evolving factors associated with long-term vision loss. METHODS: We conducted a multicenter historical cohort study of children treated in France with up-front BB-SFOP chemotherapy between 1990 and 2004. Visual acuity performed at the long-term follow-up visit or within 6 months prior was analyzed. Logistic regression analysis was used to estimate the effects of clinical and radiological factors on long-term visual outcome. FINDINGS: Of the 180 patients in the cohort, long-term visual acuity data were available for 132 (73.3%) patients (median follow-up: 14.2 years; range: 6.1–25.6). At the last follow-up, 61/132 patients (46.2%) had impaired vision, and 35 of these patients (57.3%) were partially sighted or blind. Multivariate analysis showed that factors associated with a worse prognosis for long-term visual acuity were an age at diagnosis of < 1 year (OR 3.5 [95% CI: 1.1–11.2], p = 0.04), tumor extent (OR 4.7 [95% CI: 1.2–19.9], p = 0.03), intracranial hypertension requiring one or more surgical procedures (OR 5.6 [95% CI: 1.8–18.4], p = 0.003), and the need for additional treatment after initial BB-SFOP chemotherapy (OR 3.5 [95% CI: 1.1–11.9], p = 0.04). NF1 status did not appear as a prognostic factor, but in non-NF1 patients, a decrease in tumor volume with contrast enhancement after BB-SFOP chemotherapy was directly associated with a better visual prognosis (OR 0.8 [95% CI: 0.8–0.9], p = 0.04). INTERPRETATION: Our study confirms that a large proportion of children with optic pathway glioma have poor long-term outcomes of visual acuity. These data suggest new prognostic factors for visual acuity, but these results need to be confirmed further by large- and international-scale studies.
format Online
Article
Text
id pubmed-6407847
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64078472019-03-17 Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort Rakotonjanahary, Josué Gravier, Nicolas Lambron, Julien De Carli, Emilie Toulgoat, Frédérique Delion, Matthieu Pellier, Isabelle Rialland, Xavier PLoS One Research Article BACKGROUND: Visual outcome is one of the main issues in the treatment of optic pathway glioma in childhood. Although the prognostic factors of low vision have been discussed extensively, no reliable indicators for visual loss exist. Therefore, we aimed to define initial and evolving factors associated with long-term vision loss. METHODS: We conducted a multicenter historical cohort study of children treated in France with up-front BB-SFOP chemotherapy between 1990 and 2004. Visual acuity performed at the long-term follow-up visit or within 6 months prior was analyzed. Logistic regression analysis was used to estimate the effects of clinical and radiological factors on long-term visual outcome. FINDINGS: Of the 180 patients in the cohort, long-term visual acuity data were available for 132 (73.3%) patients (median follow-up: 14.2 years; range: 6.1–25.6). At the last follow-up, 61/132 patients (46.2%) had impaired vision, and 35 of these patients (57.3%) were partially sighted or blind. Multivariate analysis showed that factors associated with a worse prognosis for long-term visual acuity were an age at diagnosis of < 1 year (OR 3.5 [95% CI: 1.1–11.2], p = 0.04), tumor extent (OR 4.7 [95% CI: 1.2–19.9], p = 0.03), intracranial hypertension requiring one or more surgical procedures (OR 5.6 [95% CI: 1.8–18.4], p = 0.003), and the need for additional treatment after initial BB-SFOP chemotherapy (OR 3.5 [95% CI: 1.1–11.9], p = 0.04). NF1 status did not appear as a prognostic factor, but in non-NF1 patients, a decrease in tumor volume with contrast enhancement after BB-SFOP chemotherapy was directly associated with a better visual prognosis (OR 0.8 [95% CI: 0.8–0.9], p = 0.04). INTERPRETATION: Our study confirms that a large proportion of children with optic pathway glioma have poor long-term outcomes of visual acuity. These data suggest new prognostic factors for visual acuity, but these results need to be confirmed further by large- and international-scale studies. Public Library of Science 2019-03-08 /pmc/articles/PMC6407847/ /pubmed/30849081 http://dx.doi.org/10.1371/journal.pone.0212107 Text en © 2019 Rakotonjanahary et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rakotonjanahary, Josué
Gravier, Nicolas
Lambron, Julien
De Carli, Emilie
Toulgoat, Frédérique
Delion, Matthieu
Pellier, Isabelle
Rialland, Xavier
Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
title Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
title_full Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
title_fullStr Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
title_full_unstemmed Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
title_short Long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front BB-SFOP chemotherapy—Analysis of a French pediatric historical cohort
title_sort long-term visual acuity in patients with optic pathway glioma treated during childhood with up-front bb-sfop chemotherapy—analysis of a french pediatric historical cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407847/
https://www.ncbi.nlm.nih.gov/pubmed/30849081
http://dx.doi.org/10.1371/journal.pone.0212107
work_keys_str_mv AT rakotonjanaharyjosue longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT graviernicolas longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT lambronjulien longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT decarliemilie longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT toulgoatfrederique longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT delionmatthieu longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT pellierisabelle longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort
AT riallandxavier longtermvisualacuityinpatientswithopticpathwaygliomatreatedduringchildhoodwithupfrontbbsfopchemotherapyanalysisofafrenchpediatrichistoricalcohort